This is Part 1 of Navigating the T-Cell Therapy Landscape in Multiple Myeloma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. 

 

In this video, Drs. Kenneth Anderson, Ajai Chari, and Noopur Raje discuss the treatment of a patient with newly diagnosed multiple myeloma. The patient is a 65-year-old man who presents with back pain. He is found to have IgG kappa 4.5 g/dL, kappa:lambda ratio of 250, and 70% bone marrow plasma cells with 1q amplification and t(4:14). His calcium and renal function are normal, but he is found to have diffuse bone disease.

 

In the conversation that follows, the faculty discuss the many quadruplet induction therapies that may be an option for this patient, the role that measurable residual disease plays in determining the best course of therapy, whether autologous stem cell transplant is still necessary, and how they are incorporating CAR T-cell therapy and bispecific T-cell engagers into the initial management of newly diagnosed multiple myeloma.